Article

First thalidomide clinical trial in multiple myeloma: A decade

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Blood (Impact Factor: 10.43). 05/2008; 112(4):1035-8. DOI: 10.1182/blood-2008-02-140954
Source: PubMed

ABSTRACT The clinical outcomes of 169 patients enrolled in the first clinical trial of thalidomide for advanced or refractory myeloma are updated. Seventeen patients remain alive and 10 are event-free, with a median follow-up of 9.2 years. According to multivariate analysis of pretreatment variables, cytogenetic abnormalities, present in 47% of patients within 3 months of enrollment, and lambda light chain isotype both affected overall survival and event-free survival adversely. Forty percent of the 58 patients lacking these 2 unfavorable features, one-half of whom had no disease recurrence, survived at least 6 years, in contrast to fewer than 5% among those with 1 or 2 risk features (P < .001). Patients who had received cumulative thalidomide doses in excess of 42 g in the first 3 months enjoyed superior overall and event-free survival. The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma.

Download full-text

Full-text

Available from: Sundar Jagannath, Mar 20, 2014
0 Followers
 · 
100 Views
 · 
25 Downloads
  • Source
    • "Neovascularization plays an important role in the pathogenesis of MM and myeloma plasma cells in majority of MM patients express VEGF. Thalidomide has been used as a common therapy for MM patients because of its antiangiogenic activity [37], [38]. Since tumor-associated MDSCs can stimulate neovascularization by forming tumor endothelium in other cancer models [8], it is possible that myeloma-associated MDSCs can form tumor endothelium during myelomagenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoclasts play a key role in the development of cancer-associated osteolytic lesions. The number and activity of osteoclasts are often enhanced by tumors. However, the origin of osteoclasts is unknown. Myeloid-derived suppressor cells (MDSCs) are one of the pre-metastatic niche components that are induced to expand by tumor cells. Here we show that the MDSCs can differentiate into mature and functional osteoclasts in vitro and in vivo. Inoculation of 5TGM1-GFP myeloma cells into C57BL6/KaLwRij mice led to a significant expansion of MDSCs in blood, spleen, and bone marrow over time. When grown in osteoclastogenic media in vitro, MDSCs from tumor-challenged mice displayed 14 times greater potential to differentiate into mature and functional osteoclasts than those from non-tumor controls. Importantly, MDSCs from tumor-challenged LacZ transgenic mice differentiated into LacZ+osteoclasts in vivo. Furthermore, a significant increase in tumor burden and bone loss accompanied by increased number of osteoclasts was observed in mice co-inoculated with tumor-challenged MDSCs and 5TGM1 cells compared to the control animals received 5TGM1 cells alone. Finally, treatment of MDSCs from myeloma-challenged mice with Zoledronic acid (ZA), a potent inhibitor of bone resorption, inhibited the number of osteoclasts formed in MDSC cultures and the expansion of MDSCs and bone lesions in mice. Collectively, these data provide in vitro and in vivo evidence that tumor-induced MDSCs exacerbate cancer-associated bone destruction by directly serving as osteoclast precursors.
    PLoS ONE 11/2012; 7(11):e48871. DOI:10.1371/journal.pone.0048871 · 3.23 Impact Factor
  • Source
    • "In spite of the teratogenic effect of thalidomide, it has been found that thalidomide is useful in treating multiple myeloma patients [56] [57]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been found that nonsense mutation R419X of cereblon (CRBN) is associated with autosomal recessive non-syndromic mental retardation. Further experiments showed that CRBN binds to the cytosolic C-terminus of large-conductance Ca(++) activated potassium channel (BK(Ca)) α-subunit and the cytosolic C-terminus of a voltage-gated chloride channel-2 (ClC-2), suggesting that CRBN may play a role in memory and learning via regulating the assembly and surface expression of BK(Ca) and ClC-2 channels. In addition, it has also been found that CRBN directly interacts with the α1 subunit of AMP-activated protein kinase (AMPK) and prevents formation of a functional holoenzyme with regulatory subunits β and γ. Since AMPK is a master sensor of energy balance that inhibits ATP-consuming anabolic pathways and increases ATP-producing catabolic pathways, binding of CRBN with α1 subunit of AMPK may play a role in these pathways by regulating the function of AMPK. Furthermore, CRBN interacts with damaged DNA binding protein 1 and forms an E3 ubiquitin ligase complex with Cullin 4 where it functions as a substrate receptor in which the proteins recognized by CRBN might be ubiquitinated and degraded by proteasomes. Proteasome-mediated degradation of unneeded or damaged proteins plays a very important role in maintaining regular function of a cell, such as cell survival, dividing, proliferation and growth. Intriguingly, a new role for CRBN has been identified, i.e, the binding of immunomodulatory drugs (IMiDs), e.g. thalidomide, to CRBN has now been associated with teratogenicity and also the cytotoxicity of IMiDs, including lenalidomide, which are widely used to treat multiple myeloma patients. CRBN likely plays an important role in binding, ubiquitination and degradation of factors involved in maintaining function of myeloma cells. These new findings regarding the role of CRBN in IMiD action will stimulate intense investigation of CRBN's downstream factors involved in maintaining regular function of a cell.
    International Journal of Biochemistry and Molecular Biology 01/2011; 2(3):287-94.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is considered predominantly a cancer of the elderly with a median patient age of 60–65 years at diagnosis and 88% of patients being over 55 years. The disease has remained incurable with a mean survival period of about 3 years for the last 30 years. In the last decade, three useful cancer drugs, namely, thalidomide, lenalidomide, and bortezomib, have been approved by the FDA to append the armamentarium of MM chemotherapy other than the standard combination of melphalan and prednisone that have been used since the 1960 s. Many clinical trials supported by in vitro laboratory investigations have been conducted to understand both the efficacy and mechanisms of the action of these cancer drugs. This brief review aims to provide an overview of new cancer drugs targeting MM and discuss the development of novel strategies for targeting this incurable disease. Drug Dev Res 69:451–459, 2008. © 2008 Wiley-Liss, Inc.
    Drug Development Research 11/2008; 69(7):451 - 459. DOI:10.1002/ddr.20275 · 0.73 Impact Factor
Show more